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The  effect of  phenylalanine and glycine  on  chloramphenicol (CAP)  induced  bone marrow toxicity 
in  albino rats  infected  with  Klebsiella pneumoniae  was  investigated.  The aim was investigate whether the 
treatment of the infected rats with either of these amino acids or their combination could reverse the major 
bone marrow toxicity of CAP.  The study lasted for a period of 21 days in which haematological and 
histopathological changes were monitored in the infcted rats. After  7 days, the  rats  became  anaemic  after  
treatment  with  CAP, but  amino acids  combined groups suppressed  the  anaemia and  infection to  some 
extent.  At the end of 21 days, amino acids combinatio  showed significant (p<0.05) suppression of anaemi  
except in CAP/Phenylalanine/glycine (group 4).  Bone marrow examination showed the mechanism involved 
in the  suppression of  anaemia  ( amino acids  administration triggered  RBC  compensatory  mechanism  seen 
as  erythroid  hyperplasia and myeloid hypoplasia ). Histopathology changes ranges from hypocellularity in 
CAP group and fairly normocellularity in CAP/phenylalanine, CAP/glycine and necrotic/degenerative changes 
in group 4.  Single  amino acids combination with CAP have obvious protective effect and suppressed the bon  
marrow toxicity of CAP compared to the combination f the two amino acids with CAP , but all the 
combinations were effective in enhancing the efficacy of CAP. 
© 2016 International Formulae Group. All rights reserved. 
 




Chloramphenicol (CAP) is an old 
antibiotic that came into clinical practice in 
1949. It is a popular broad spectrum 
antibiotic, because of its high antimicrobial 
activity against Gram positive and Gram 
negative bacteria, Chlamydia, Rickettsia and 
Mycoplasia.  It is a potent bacteriostatic 
antibiotic that is particularly useful in 
infections caused by Salmonella typhi, 
meningitides and Heamophillus influenza 
(Fullers et al., 2003; Chambers, 2006; 
Dowling, 2006).  The adverse effect of  CAP  
is mainly  haematological :  aplastic  anaemia  
(Turton et al., 2002 ;  Rosenberg and Marcus, 
2008; Clark and Kumar, 2011; McCurdy, 
2011),  bone marrow suppression  (Clark and 
Kumar.,  2011),  hypersensitivity reactions 
includes optic neuropathy, skin reaction  
(Chambers, 2006).  CAP is one of the 
common drugs that causes pancytopenia 
(Chen, 2005). It is the major problem of this 
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drug worldwide. Despite  the bann  placed on 
the use of the drug because of these  
haematoxic  and other  adverse effects , the 
drug continues to be used in many part of the 
world  because of  its  availability  and  cost 
effectiveness  over  the  newer  antibiotic  
(Ruef and Blaser, 2000). Nevertheless, the 
global problem of advancing bacterial 
resistance to newer drugs has led to review 
interest in its use (Falagas et al., 2008).  
Studies  done by   Effiong et al. (2010),  
Hossam et al. (2010)  among others was 
effective in  reducing  the  toxic  effect  of  
CAP  but the  efficacy was affected.  
Exception was seen in the study done by 
Chilaka et al. (2005) and Esimone et al. 
(2007). Their study improved on the 
antibacterial effect of the drug  because they 
used amino acids, Chilaka et al. (2005)  
worked on  peripheral blood only  while  
Esimone et al. (2007)   study the effects  on  
peripheral  blood  and  organs (liver and 
spleen). Their studies were not extended to the 
bone marrow where there is major toxicity. 
These amino acids (phenylalanine and 
glycine) were effective because they were 
found to have protective and antibacterial 
effect. Their  protective  effects  were 
confirmed by the studies  of  (Asakhiors et al., 
2000;  Yin et al., 2002;  Zhou et al., 2005;  
Senthikumar et al., 2004;  Para-vizuet et al., 
2009; Yolande et al., 2011; Ponjit et al., 2011;  
Manion et al., 2011),  while their  antibacterial  
effect  were  supported by the studies   of  
Minami et al., 2004;  Sharma et al., 2012).  
Due to the limitations of most  of  the  CAP  
toxicity  reduction studies  above  and  to 
sustain  the therapeutic value of CAP in 
specific indications  especially  in  developing 
countries,  we  decided to carry out study 
directly on bone marrow with the aim to  
study  the  effects  of  phenylalanine (an 
hydrophobic aromatic ring amino acid)  and 
glycine  (an  hydrophilic straight chain amino 
acids) on haematological and 
histopathological profile of CAP- induced 
bone marrow toxicity in albino rats infected 
with Klebsiella pneumoniae. 
 
 
MATERIALS AND METHODS  
Preparation of inoculum 
The test organism Klebsiella 
pneumoniae was purified after gram staining 
by streaking in sterile nutrient agar plates. 
Maintenance and cultivation of the organism 
were carried out by weekly subculturing   on 
different nutrient agar slants. The agar slants 
were stored in a refrigerator at   4 oC after 24 
hrs incubation at 37 oC. The organism was 
activated before use by successive 
subculturing in 10 ml sterile   nutrient agar 
slant for 3 consecutive days. In each case ,the  
inoculum  was usually  24 hrs  old  culture of  
Klebsiella pneumoniae, standard  inoculum  
size  of  0.5x106  CFUf/ml (Mc Farland)  was 
used for the test. 
 
Animal and experimental design 
Thirty  albino rats of about  two-three 
months  weighing  of  about  90-120 g  were  
obtained from  the  animal  house of  the  
pharmaceutical  science,   Nnamdi Azikiwe 
University  (Unizik)  Agulu  branch,  they  
were  acclimatized  in  pharmacology  
laboratory  for  one  week  before the 
beginning  of the experiment.  They were fed 
with commercial growers feed, also they had 
access to clean drinking water. The animals 
were randomly divided into five groups of 
each comprising 4 test groups and 1 control 
groups containing   six animals each. Infection 
of  Klebsiella pneumoniae  was  induced by 
single  intraperitoneal injection of   0.5 ml of 
freshly  prepared  inoculum of  Klebsiella  
pneumoniae   in normal  saline  to  all the 
groups, followed  immediately by the 
intraperitoneal administration of the 
following. Group 1: 5.0 mg/kg bw of 
chloramphenicol (CAP) only;         
Group 2: 5.0 mg/kg bw of CAP + 2.0 mg/kg 
bw of phenylalanine; 
Group 3: 5.0 mg/kg bw of CAP +5.0 mg/kg 
bw of glycine; 
Group 4: 5.0 mg/kg /bw of CAP +2.5mg/kg 
bw of phenylalanine +5.0mg/kg bw of glycine 
Group 5:  no treatment (control). 
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Drug dilutions were made with sterile 
normal saline.  The animals were observed 
daily for disease or any overt sign of toxicity. 
On the 21st day, the survivors were sacrificed 
and monitored histopathologically. 
 
Collection of blood 
Blood for haematological examination 
was collected by ocular puncture:  each 
animal was anesthetized with diethylether 
using heparinised capillary tubes, blood flows 
from retinal vein directly into plastic tubes 
containing  EDTA (ethylenediaminetetraacetic 
acid).  Blood samples was collected three 
times for haematological analysis which 
include blood for pre-treatment test (day 
zero),  on the 7th and 21st  days  post treatment. 
 
Haematological /Histopathology analysis 
Haematological analysis were carried 
out using the following methods:  Pack cell 
volume (PCV) and haemoglobin 
concentration (HB) were determined by 
microhaematocrit and sahli methods  
respectively. Reticulocyte count were 
determined by  supravital  staining techniques 
using  New methylene blue stain also 
leishman stain  was used  for  White blood 
cell  differential count .  Reticulocyte index 
(RI) was calculated by multiplying 
reticulocytes counted with PCV and divide by 
HB. Total White blood cell count was done 
using hemocytometer method. They were 
determined according to the standard methods 
described earlier (Cheesebrough., 2002).  
Bone marrow aspirates was stained with 
leishman stain followed by bone marrow 
differential count and calculation of myeloid 
erythroid ratio.  The survival animals were 
sacrificed on the 21st  day, sections of the  
bones  were  fixed  in 10% formalin  for 24hrs 
for bone marrow  histopathological analysis 
which involved the following stages 
decalcification, paraffin embedded, 
hematoxylin and eosin (H&E) stained section 




Statistical   analysis            
The results  of this study were analysed 
using  Salstat-statistical package 2, in which 
all the results were expressed as  mean ±  
standard  deviation of mean  (SDM)  and  
Student  t-test  and hypothetical test was used 
to  assess  statistical significance in  various 
groups of  animals. Differences in paired 
mean observation were regarded as significant 
at p < 0.05. 
 
RESULTS   
It was observed that two out of the four 
animals in group 5 (infected but not treated) 
died before the 7th day. The following pattern 
of death were recorded in the test groups: 
group1: (1), group 2: (1), group 3 : (1)  group 
4 : (2).  The haematological indices  on the 7th 
day indicated that there was decrease in 
packed cell volume (PCV), haemoglobin (HB) 
, reticulocyte count  and reticulocyte index 
(RI) and these values were statistically 
different  from  pre-treatment values  (p 
<0.05).  In contrast, there was increase in 
WBC total count which was not significant 
(p>0.05) in the test groups. There was 
significant (p<0.05) lymphocytosis and 
neutropenia in WBC differential count of 
CAP alone and CAP/phenylalanine /glycine 
groups, also, there was neutrophilia in the 
control groups. The blood picture report 
showed the presence of hypochromic RBC 
and thrombocytopenia in group 1 and 4 
(Tables 1 and 2).   The result of 
haematological indices on day 21 compared to 
that on the  7th  day  indicated  that there was 
significant  ( p < 0.05)  increase in RBC  
haematological  indices in all the groups 
except in group 1 (CAP alone) and 4 
(CAP/phenylalanine /glycine). In contrast the 
increase in WBC was controlled on the 7th day 
by the test groups, therefore   there was no 
significant (p > 0.05) decrease on the 21st day. 
There was significant (p<0.05) decrease  in 
lymphocytes  in  WBC  differential  count, 
returning  the  blood picture  to normal except 
in group 1 and 4  that had  persistent 
neutropenia (Table 3).   The  result of  
haematological examination  of  bone marrow  
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showed that there  was  erythroid  hyperplasia  
and myeloid  hypoplasia in all the  groups  
except in CAP group that had severe  
erythroid  hypoplasia  of -13 of 26.5 (-50%). 
There was general decrease in myeloid 
erythroid ratio in all the groups, but it was 
severe in group 1 and 4 (Table 4).        
Histopathology  result of  bone marrow  
in group 1 showed  that  there is no significant  
changes in the bone marrow architecture, but  
there  was moderate  to severe  
haematopoiesis   with  subsequent  increased  
adipocytes  that resulted to hypocellularity  
signifying  the  presence of   aplastic anaemia.  
In group 2, there is also no significant changes 
in the bone marrow   architecture, but there 
was moderate to less severe haematopoiesis 
with decreased adipocytes that resulted to 
fairly normocellularity.  CAP/ glycine group, 
the  picture  shows that  there  was  clotted  
bone marrow, a sign that  healing  process had   
commenced resulting  to fairly  
normocellularity. In CAP/phenylalanine 
/glycine group the bone marrow picture 
showed that there was a degenerative/necrotic 
change with complete distortion of bone 
marrow architecture.  Finally,  the   Control 
group  showed that  there was normal bone 
marrow  with normal distribution  and 
cellularity, also  several distinct  
megakaryocytes  can be  recognized  because 
of their large size and multiple nuclear lobes 
(Figures 1-5).   
From  the above  results, the  potency  
of the drug  used in  the  treatment   was  
analysed , that of  anaemia  was evaluated   by 
noting the dose of  the drugs  that caused  
percentage    decrease  after  7 days  and     
increase  after  21 days  in RBC  
haematological  indices.  It was observed  that   
the  treatment  that  caused  high increase  
after  21 days  had  compensatory  effect  on  
RBC  that was  initially  decreased  by  
chloramphenicol  administration   after 7 days. 
These  observations  was  confirmed  by  the 
increase of  122.6%   erythroid  hyperplasia  
and  histopathology  changes. Therefore,  
treatment in  group 2  (5mg of CAP + 2.5mg 
of phenylalanine)   was  most  potent  
followed by  group 3  (5mg of CAP+5mg of 
Glycine)  with  90.5%, while  treatment  in  
group 1 and 4 was not  potent  (Table 5). 
Potency of  drug used  in the treatment of  
infection   was  also evaluated  by noting  the  
dose  that caused  increase  effect  after 7 days  
and  decrease  effect  after  21 days on  WBC 
total count.  It was observed  that  the  
treatment with less  increase  effect  and  high  
decrease  effect  on WBC count  were  more  
potent,  therefore, group 3  was  most potent  
followed  by  group 1. Finally, group 4 was 





Figure 1: (Bone marrow photomicrograph of group 1). Top arrowhead pointing at areas of 
hypocellularity and increased adipocytes (whitish) ignifying the presence of aplastic anaemia. 
Down arrowhead is pointing at the section of bone. 





Figure 2:  (Bone marrow photomicrograph of group 2). The arrowhead pointing at area of moderate 




Figure 3: (Bone marrow photomicrograph of group 3).The arrowhead is pointing at clotted bone 
marrow resulting to healing to fairly normocellularity. 
 
 
Figure 4: (Bone marrow photomicrograph of group 4).  The arrowhead is pointing at area of 
degenerative/necrotic changes. 
 
                                               









Table1:   Pre-treatment (baseline) haematological data.  
 
Groups 1 2 3 4 5 
Mean wt (kg) 
PCV(%) 
HB (g/ml) 
Reticulocyte count (%) 
Reticulocyte index 
WBC total count (x103,102) 
Neutrophils 
Lymphocytes 
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Table 2:   Effect of administration of phenylalanine and glycine on CAP induced bone marrow toxicity in rats infected with Klebsiella pneumoniae. 
 
Treatment CAP CAP /Pheln CAP/glycine CAP/pheln/glycine No Treatment 
PCV (%) 
HB (g/ml) 
Reticulocyte count (%) 
Reticulocyte index 
WBC total count (x 103 
Neutrophil 
Lymphocytes 









































 (Significant  p<0.05,values  in parenthesis represents percentage decrease (-) or increase (+)  in respective indices  on the 7th day in relative to  pre-treatment data.).     Thrbcp = Thrombocytopenia  , 

















Table 3: Effect of administration of amino acids (phenylalanine and glycine on chloramphenicol (CAP) induced bone marrow toxicity in rats infected 
with Klebsiella pneumoniae  on  the 21st day. 
 
Groups 1 2 3 4 5 
PCV (%) 
HB (g/ml) 
Average %∆ in PCV/ HB  
Reticulocyte count (%) 
Reticulocyte index 
WBC total count (x 103 
Neutrophil 
Lymphocytes 























1.32±0.04(+53.  4) 























(Significant p<0.05) % increase (+) in PCV/HB, Reticulocyte count and Reticulocytes index (index for amelioration of anaemia) and decrease (-) in WBC count (index for remission of 

















Table 4: Effect of administration of phenylalanine and glycine on bone marrow count of survival rats after 21 days.      
 
Groups 1 2 3 4 5 
MYELOID CELLS 
















































RBC Blast  NV :(25.6%) 
RMKS 
M .E  Ratio 
 
12.0±3.60 (-50) 


















 (Significant p< 0.05: percentage decrease (-) in myeloid cells (WBC Blast),(index for neutropenia caused by CAP administration)  and  increase  (+)   in erythroid cells (RBC Blast), (index for RBC 
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Table 5: Evaluation of potency of the drug used in treatment of bone marrow  suppression  and   aplastic  anaemia. 
 
Treatment CAP CAP/Phenylalanine CAP/glycine CAP/Phenyl/glycine 
Dose (mg) (5.0) (5.0 +2.5) (5.0+5.0) (5.0+2,5+5.0) 
% Decrease in RBC IND after 7 days 
PCV/HB 
Reticulocyte  count 

















%  Increase in RBC  1ND  after 21days 
PCV/HB 
Reticulocyte  count 

















% Decrease  in Myeloid   cell 














Less percentage decrease  ( - )  after 7 days  and  high percentage   increase  (+ )   after  21days   in  RBC indices,  followed by high % increase   (+)  of  erythroid cells  (hyperplasia).  ( an  index 
for  greater   potency   in  amelioration of  aplastic anaemia  and  bone marrow  suppression ) . SS =low and  Steady , IND=Indices. 
 
 
Table 6: Evaluation of potency of the drugs used in the treatm nt of  Klebsiella  pneumoniae. 
 
Treatment CAP CAP/Phenylalanine CAP/ glycine CAP/Phenyl/glycine 
Dose  (mg) 
%  Increase in WBC  after 7 days 





Potent with fast action 
(5.0 + 2.5) 
+(30.0) 
-(3.40) 
Potent  with slow action 
(5.0 + 5.0) 
+(5.40) 
-(33.0) 




Potent with slow action 
Less percentage increase  (+)  after 7 days and  high percentage decrease  (--)  after  21 days in WBC total count.   (Index for greater potency in remission of infection of   Klebsiella pneumoniae).  Phenyl = 
Phenylalanine. 




In CAP treated group, there was 
anaemia, reticulocytopenia and decrease 
reticulocyte index, evident that there was 
general decrease in overall erythroid activity 
(in peripheral blood and bone marrow) after 
21 days. Severe erythroid hypoplasia  and 
myeloid hypoplasia in bone marrow aspiration 
count, followed by  neutropenia, and 
thrombocytopenia in the blood picture 
confirmed  pancytopenia  (a feature of aplastic 
anaemia) in the group, supported by the 
findings of  Chen (2005);  Clark and Kumar 
(2011). Histopathology result of 
hypocellularity in the group confirmed the 
findings that CAP causes aplastic anaemia 
(Rich et al., 1950; Daum et al., 1997; Holt and 
Bajoria, 1999; Turton et al., 2002; Smick et 
al., 2004; Chen, 2005; McCurdy, 2011).   
CAP/Phenylalanine combination was able to 
control anaemia caused by CAP 
administration.  Bone marrow count of  
increased  erythroid  hyperplasia of 122%  
showed that phenylalanine  administration  
triggered  RBC  compensatory  mechanism  to  
supress  the  anaemia caused  by  CAP,  and  
finally histopathology  result of  fairly  
normocellularity, correlates  with earlier  
study that phenylalanine reverses the toxic 
effect of  CAP  (Ingall et al., 1965) .  Studies  
by  (Zhou  et al., 1997 ;  Ichiyama  et al., 
1999;  Askhiors  et al., 2000 ;  Manion  et al., 
2011) also  confirmed the protective  effects 
of  phenylalanine .  CAP/glycine  combination  
also  was  able to control anaemia caused by  
CAP  administration,  concurrent  
administration  produced negligible  
percentage difference  in the red cell indices 
on day 21 when compared with the values 
obtained on day 7.  This shows that the ability 
of the combination to control anaemia peaked 
on day 7 and remained almost constant till day 
21. Bone marrow  erythroid  hyperplasia of  
90.5% showed  that glycine  also triggered  
RBC compensatory   mechanism  to  supress  
the  anaemia. Its slow and steady action was 
confirmed by the clotting mechanism it uses 
to return to fairly normocellularity in 
histopathology result.  These  findings 
confirmed  the protective  effect of  glycine,  
that  was  earlier  supported  by the studies of  
(Zhou  et al., 1997 ; Jacob et al., 2003;  
Senthilkumar  et al., 2004;  Para-vizuet et al., 
2009;   Ponjit et al., 2011). The  mechanism of 
protective effects of glycine  is partially 
explained by glycine inhibitory effect  it can 
hyperpolarized certain immune cells via 
glycine gated chloride channels decreasing the 
amount of toxic mediated  (TNT-α,1L-6) 
release in response to endotoxin and other 
stimuli (Froh et al., 2002).  In 
CAP/phenylalanine/glycine combination, the 
histopathology result of degenerative/necrotic 
changes confirmed the persistent bone marrow 
suppression, decreased RBC compensatory 
effect of 5,4% erythroid  hyperplasia  and  
neutropenia. The 5.4% erythroid hyperplasia 
showed that the combination have little effect 
on suppression of anaemia, which was 
supported by the findings of (Chilaka et al., 
2005; Esimone et al., 2007).   This finding  
further  explain the fact that  chloramphenicol 
interferes  with the folic acid uptake thereby 
inducing  anaemia  but  glycine and 
phenylalanine combination with CAP  play a 
role in increasing the  folate carrier and 
thereby  reducing anaemia  (Tse et al., 1998). 
The histopathology  findings  explained that 
the combination can only suppress  anaemia at 
the peripheral blood level  but could not  
protect  the bone marrow,  which was  
supported  by  the  findings  of  Esimone et al.  
(2007) that  the combination did not protect 
the blood forming organs : (liver and spleen) 
as their  histopathology  section  showed  
degeneration /necrotic changes and congested 
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red pulp  with  moderate  to  severe  
haemosiderosis  respectively.  The  ability of  
the  above  mentioned combinations 
(CAP/phenylalanine, CAP/glycine  and 
CAP/phenylalanine/ glycine) to control 
progression of  infection of  Klebsiella 
pneumoniae  peaked  on  the  day 7  till day 
21, their  ability to do so  was confirmed  with  
result of  statistical analysis  of  no  significant  
increase  (p > 0.05)  in  WBC  total  count.  
CAP/glycine  was  most  remarkable  in  the  
control  of  infection  which was  supported  
by  the  fact  that  glycine   have  antibacterial 
effect  (Hishinuma et al., 1970 ; Tomoeda, 
1976;  Minami et al., 2004) . The  proposed  
mechanism   by  which  glycine  increase  the  
antibacterial  activity  of  CAP is  as a result 
of its ability to  inhibits the  synthesis of a  
peptidoglycan  component of the bacterial cell 
wall  (Minami et al., 2004) . Based on the 
mechanism, glycine produce synergistic effect 
when combined with CAP, thereby increase 
its antibacterial effect. CAP / phenylalanine 
combination   antibacterial effect was 
supported by the finding of (Cockburn et al., 
1965; Sharma et al., 2012). The finding of 
Sharma  et al. ( 2012)   states that  
phenylalanine  (a peptide drug)  produce  
synergistic effect  when  combined  with  non-
peptide drug and can be used to battle  
increasingly drug- resistant  microbes.  Based 
on the finding of Sharma et al. (2012), CAP (a 
non-peptide drug) combined with 
Phenylalanine (a peptide drug) produced 
increase effect; this might be the proposed 
mechanism of phenylalanine increased 
antibacterial effect with CAP. 
 
Conclusion 
The result of the study  showed that 
CAP  causes anaemia (bone marrow 
suppression and aplastic anaemia) but the  
combination  with  phenylalanine or  glycine  
caused reduction in all the bone marrow toxic 
effects  while  combination of  the two amino 
acids  with  CAP  have very significant effect 
only in  peripheral  blood  in  reduction  of 
anaemia.  All the combinations increased 
antibacterial effect of CAP. 
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